South & Central America Radiopharmaceutical Theranostics Market Forecast to 2028

South & Central America Radiopharmaceutical Theranostics Market Forecast to 2028 – Regional Analysis – by Product Type (Alpha Emitters, Beta Emitters, and Positron Emission Tomography (PET) Tracers), Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others); Source (Nuclear Reactors and Cyclotrons), Application (Targeted Therapeutic [Rx] and Companion Diagnostic [CDx]); Indication (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Diagnostic Imaging Centers, Academic and Research Institutes, and Others)

Send Enquiry
Item ID: BMIRE00029008 Category: Tags: , ,

$2,100$3,500

Description

The South & Central America radiopharmaceutical theranostics market was valued at US$ 129.48 million in 2022 and is expected to reach US$ 233.71 million by 2028; it is estimated to register a CAGR of 10.3% from 2022 to 2028.

Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies fuel the South & Central America Radiopharmaceutical Theranostics Market

Radiopharmaceutical therapies (RPTs) involve injecting a particular radioactive drug (such as 200mCi for Lu-177-PSMA and Lu-177-DOTATATE) into all patients undergoing therapy. However, upon injection, the doses delivered to organs and absorbed qualities of drugs show notable variations. Radiopharmaceutical therapies for tumors and normal tissues depend on absorbed doses; however, variations in absorption are difficult to control. A fixed administered dosage results in the undertreatment of patients, possibly leading to cases of dose toxicity. Theranostic digital twins (TDTs) can be employed in the drug development process to overcome such limitations. The TDTs investigate optimal injected radioactive drugs among patients at the sites of injection, along with determining injection intervals and profiles, and suitable combinational radiopharmaceutical therapies. Additionally, TDTs coupled with appropriate computational tools can be used in predictive absorbed radiation dose modeling. Further, TDTs promise zero uncertainties in the clinical results generated, thus acting as a powerful tool for offering truly personalized treatments to patients. Thus, the use of TDTs in personalized radiopharmaceutical therapies provides lucrative opportunities for radiopharmaceutical theranostics market players.

South & Central America Radiopharmaceutical Theranostics Market Overview

The South & Central America radiopharmaceutical theranostics market is segmented into the Argentina, Brazil, and the rest of South & Central America. The market growth in this region is due to the increasing prevalence of cancer and cardiovascular diseases, and presence of supportive government plans. Growing diabetes who are prone to cardiovascular disease is promoting the growth of radiopharmaceutical theranostics market in Brazil. Further, expanding healthcare expenditure in Brazil is boosting the radiopharmaceutical theranostics market.

South & Central America Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Radiopharmaceutical Theranostics Market Segmentation

The South & Central America radiopharmaceutical theranostics market is segmented based on product type, radioisotype, source, application, indication, end user, and country. Based on product type, the South & Central America radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The Positron Emission Tomography (PET) tracers segment held the largest market share in 2022.

Based on radioisotype, the South & Central America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.

Based on source, the South & Central America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.

Based on application, the South & Central America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held a larger market share in 2022.

Based on indication, the South & Central America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.

Based on end user, the South & Central America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022.

Based on country, the South & Central America radiopharmaceutical theranostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America radiopharmaceutical theranostics market share in 2022.

Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers are some of the leading companies operating in the South & Central America radiopharmaceutical theranostics market.

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

At 10.3% CAGR, the South & Central America Radiopharmaceutical Theranostics Market is Speculated to be worth US$ 233.71 million by 2028, saysthe research team

According tothe research team research, the South & Central America radiopharmaceutical theranostics market was valued at US$ 129.48 million in 2022 and is expected to reach US$ 233.71 million by 2028, registering a CAGR of 10.3% from 2022 to 2028. Rising incidence of cancer and rising application in treatment of cardiovascular disorders are the critical factors attributed to the South & Central America radiopharmaceutical theranostics market expansion.

Theranostics in nuclear medicine gathers researchers’ interest through molecular imaging and personalized medicine. This is achieved through assistance in the management of various diseases, improves patient selection process, predicts drug response and toxicity, determines prognosis, and helps avoid futile and costly/expensive examinations and treatments. The theranostic approach to nuclear medicine involves a combination of diagnostic imaging and therapy based on a radioactive drug; its primary focus is the diagnosis, while the secondary focus is the treatment of a tumor site. Radioiodine was the first theranostic radiopharmaceutical used in treating and imaging thyroid diseases. In radioiodine therapy, the radioisotope iodine-131 is a gamma and beta emitter, and the sodium-iodide symporter can directly mediate the gamma emitter to thyroid cells. Further, gamma and positron emitters (?+) are used in nuclear imaging. Gamma emitters such as technetium-99m or iodine-123 are used in SPECT imaging, whereas the use of gallium-68 and fluorine-18 in PET imaging can provide better resolution. Therefore, theranostics-based nuclear-targeted therapies are emerging as a useful tool for treating in patients suffering from advanced neuroendocrine and gastroenteropancreatic tumors such as neuroblastomas. This is expected to drive the South & Central America radiopharmaceutical theranostics market during the forecast period.

On the contrary, regulatory challenges for approval of radiopharmaceutical theranostics hurdles the growth of South & Central America radiopharmaceutical theranostics market.

Based on product type, the South & Central America radiopharmaceutical theranostics market is categorized into alpha emitters, beta emitters, and positron emission tomography (PET) tracers. The positron emission tomography (PET) tracers segment held 42.9% market share in 2022, amassing US$ 55.60 million. It is projected to garner US$ 103.68 million by 2028 to expand at 10.9% CAGR during 2022–2028.

Based on radioisotope, the South & Central America radiopharmaceutical theranostics market is categorized into technetium-99, gallium-68, iodine-131, iodine-123, fluorine-18 (18F), yttrium 90 (Y-90), Lutetium (Lu) 177, copper (Cu) 67, copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held 26.4% market share in 2022, amassing US$ 34.15 million. It is projected to garner US$ 65.06 million by 2028 to expand at 11.3% CAGR during 2022–2028.

Based on source, the South & Central America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held 63.8% market share in 2022, amassing US$ 82.66 million. It is projected to garner US$ 157.69 million by 2028 to expand at 11.4% CAGR during 2022–2028.

Based on application, the South & Central America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held 61.9% market share in 2022, amassing US$ 80.09 million. It is projected to garner US$ 146.63 million by 2028 to expand at 10.6% CAGR during 2022–2028.

Based on indication, the South & Central America radiopharmaceutical theranostics market is categorized into oncology, cardiology, neurology, and others. The oncology segment held 64.6% market share in 2022, amassing US$ 83.70 million. It is projected to garner US$ 156.23 million by 2028 to expand at 11.0% CAGR during 2022–2028.

Based on end user, the South & Central America radiopharmaceutical theranostics market is categorized into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held 36.1% market share in 2022, amassing US$ 46.68 million. It is projected to garner US$ 82.91 million by 2028 to expand at 10.0% CAGR during 2022–2028.

Based on country, the South & Central America radiopharmaceutical theranostics market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 61.4% share of South & Central America radiopharmaceutical theranostics market in 2022. It was assessed at US$ 79.51 million in 2022 and is likely to hit US$ 144.24 million by 2028, exhibiting a CAGR of 10.4% during 2022–2028.

Key players operating in the South & Central America radiopharmaceutical theranostics market are Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers among others.

In Oct 2021, Curium Initiates ECLIPSE, a Phase 3 Clinical Trial for Its Investigational Lu 177 PSMA I&T. In Feb 2022, Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement.

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 South & Central America Radiopharmaceutical Theranostics Market – by Product Type
1.3.2 South & Central America Radiopharmaceutical Theranostics Market – by Radioisotope
1.3.3 South & Central America Radiopharmaceutical Theranostics Market – by Source
1.3.4 South & Central America Radiopharmaceutical Theranostics Market – by Application
1.3.5 South & Central America Radiopharmaceutical Theranostics Market – by Indication
1.3.6 South & Central America Radiopharmaceutical Theranostics Market – by End User
1.3.7 South & Central America Radiopharmaceutical Theranostics Market – by Country
2. South & Central America Radiopharmaceutical Theranostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Radiopharmaceutical Theranostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 South & Central America PEST Analysis
4.3 Expert’s Opinion
5. South & Central America Radiopharmaceutical Theranostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Incidence of Cancer
5.1.2 Rising Application in Treatment of Cardiovascular Disorders
5.2 Market Restraints
5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
5.3 Market Opportunities
5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
5.4 Future Trends
5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
5.5 Impact Analysis
6. Radiopharmaceutical Theranostics Market – South & Central America Analysis
6.1 South & Central America Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis
7. South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 – by Product Type
7.1 Overview
7.2 Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
7.2.1 Positron Emission Tomography (PET) Tracers
7.2.1.1 Overview
7.2.1.2 Positron Emission Tomography (PET) Tracers: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
7.2.2 Beta Emitters
7.2.2.1 Overview
7.2.2.2 Beta Emitters: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
7.2.3 Alpha Emitters
7.2.3.1 Overview
7.2.3.2 Alpha Emitters: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8. South & Central America Radiopharmaceutical Theranostics Market Analysis – by Radioisotope
8.1 Overview
8.2 Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
8.2.1 Technetium-99
8.2.1.1 Overview
8.2.1.2 Technetium-99: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.2 Gallium-68
8.2.2.1 Overview
8.2.2.2 Gallium-68: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.3 Iodine-131
8.2.3.1 Overview
8.2.3.2 Iodine-131: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4 Iodine-123
8.2.4.1 Overview
8.2.4.2 Iodine-123: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.5 Fluorine-18 (18F)
8.2.5.1 Overview
8.2.5.2 Fluorine-18 (18F): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.6 Yttrium 90 (Y-90)
8.2.6.1 Overview
8.2.6.2 Yttrium 90 (Y-90): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.7 Lutetium (LU) 177
8.2.7.1 Overview
8.2.7.2 Lutetium (LU) 177: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.8 Copper (CU) 67
8.2.8.1 Overview
8.2.8.2 Copper (CU) 67: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.9 Copper (CU) 64
8.2.9.1 Overview
8.2.9.2 Copper (CU) 64: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2.10 Others
8.2.10.1 Overview
8.2.10.2 Others: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
9. South & Central America Radiopharmaceutical Theranostics Market Analysis – by Source
9.1 Overview
9.2 Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
9.2.1 Nuclear Reactors
9.2.1.1 Overview
9.2.1.2 Nuclear Reactors: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.2 Cyclotrons
9.2.2.1 Overview
9.2.2.2 Cyclotrons: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
10. South & Central America Radiopharmaceutical Theranostics Market Analysis – by Application
10.1 Overview
10.2 Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
10.2.1 Targeted Therapeutic (Rx)
10.2.1.1 Overview
10.2.1.2 Targeted Therapeutics (Rx): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
10.2.2 Companion Diagnostic (CDx)
10.2.2.1 Overview
10.2.2.2 Companion Diagnostics (CDx): Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11. South & Central America Radiopharmaceutical Theranostics Market Analysis – by Indication
11.1 Overview
11.2 Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
11.2.1 Oncology
11.2.1.1 Overview
11.2.1.2 Oncology: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11.2.2 Neurology
11.2.2.1 Overview
11.2.2.2 Neurology: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11.2.3 Cardiology
11.2.3.1 Overview
11.2.3.2 Cardiology: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
11.2.4 Others
11.2.4.1 Overview
11.2.4.2 Others: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12. South & Central America Radiopharmaceutical Theranostics Market Analysis – by End User
12.1 Overview
12.2 Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
12.2.1 Hospitals
12.2.1.1 Overview
12.2.1.2 Hospitals: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12.2.2 Diagnostic Imaging Centers
12.2.2.1 Overview
12.2.2.2 Diagnostic Imaging Centers: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12.2.3 Academic & Research Institutes
12.2.3.1 Overview
12.2.3.2 Academic & Research Institutes: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
12.2.4 Others
12.2.4.1 Overview
12.2.4.2 Others: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13. South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 – by Country Analysis
13.1 South & Central America Radiopharmaceutical Theranostics Market
13.1.1 Overview
13.1.2 South & Central America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
13.1.2.1 Brazil: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.1.1 Overview
13.1.2.1.2 Brazil Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.1.3 Brazil Radiopharmaceutical Theranostics Market, by Product type, 2019–2028 (US$ Million)
13.1.2.1.4 Brazil Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US$ Million)
13.1.2.1.5 Brazil Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US$ Million)
13.1.2.1.6 Brazil Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US$ Million)
13.1.2.1.7 Brazil Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US$ Million)
13.1.2.1.8 Brazil Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US$ Million)
13.1.2.2 Argentina: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.2.1 Overview
13.1.2.2.2 Argentina Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.2.3 Argentina Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US$ Million)
13.1.2.2.4 Argentina Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US$ Million)
13.1.2.2.5 Argentina Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US$ Million)
13.1.2.2.6 Argentina Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US$ Million)
13.1.2.2.7 Argentina Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US$ Million)
13.1.2.2.8 Argentina Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US$ Million)
13.1.2.3 Rest of South & Central America: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.3.1 Overview
13.1.2.3.2 Rest of South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
13.1.2.3.3 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US$ Million)
13.1.2.3.4 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US$ Million)
13.1.2.3.5 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US$ Million)
13.1.2.3.6 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US$ Million)
13.1.2.3.7 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US$ Million)
13.1.2.3.8 Rest of South & Central America Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US$ Million)
14. Radiopharmaceutical Theranostics Market – Industry Landscape
14.1 Overview
14.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
14.3 Inorganic Growth Strategies
14.3.1 Overview
14.4 Organic Growth Strategies
14.4.1 Overview
15. Company Profiles
15.1 Bayer AG
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Curium
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Telix Pharmaceuticals Ltd.
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Siemens Healthineers AG
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
16. Appendix
16.1 About
16.2 Glossary of Terms

LIST OF TABLES

Table 1. Brazil Radiopharmaceutical Theranostics Market, by Product type – Revenue and Forecast to 2028 (US$ Million)
Table 2. Brazil Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US$ Million)
Table 3. Brazil Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 4. Brazil Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 5. Brazil Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 6. Brazil Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Argentina Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. Argentina Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US$ Million)
Table 9. Argentina Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 10. Argentina Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 11. Argentina Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 12. Argentina Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 13. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US$ Million)
Table 15. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 16. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of South & Central America Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 19. Recent Inorganic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 20. Recent Organic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 21. Glossary of Terms

LIST OF FIGURES

Figure 1. South & Central America Radiopharmaceutical Theranostics Market Segmentation
Figure 2. South & Central America Radiopharmaceutical Theranostics Market, by Country
Figure 3. South & Central America Radiopharmaceutical Theranostics Market Overview
Figure 4. Positron Emission Tomography (PET) Tracers Segment Held Largest Share of Product Type Segment in Radiopharmaceutical Theranostics Market
Figure 5. Brazil Expected to Show Remarkable Growth During Forecast Period
Figure 6. South & Central America: PEST Analysis
Figure 7. South & Central America Experts’ Opinion
Figure 8. South & Central America Radiopharmaceutical Theranostics Market: Impact Analysis of Drivers and Restraints
Figure 9. South & Central America Radiopharmaceutical Theranostics Market – Revenue Forecast and Analysis – 2020–2028
Figure 10. South & Central America Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 11. Positron Emission Tomography (PET) Tracers: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Beta Emitters: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Alpha Emitters: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope, 2021 & 2028 (%)
Figure 15. Technetium-99: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Gallium-68: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Iodine-131: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Iodine-123: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Fluorine-18 (18F): South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Yttrium 90 (Y-90): South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Lutetium (LU) 177: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Copper (CU) 67: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Copper (CU) 64: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Others: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. South & Central America Radiopharmaceutical Theranostics Market, by Source, 2021 & 2028 (%)
Figure 26. Nuclear Reactors: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Cyclotrons: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. South & Central America Radiopharmaceutical Theranostics Market, by Application, 2021 & 2028 (%)
Figure 29. Targeted Therapeutics (Rx): South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Companion Diagnostics (CDx): South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. South & Central America Radiopharmaceutical Theranostics Market, by Indication, 2021 & 2028 (%)
Figure 32. Oncology: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Neurology: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Cardiology: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Others: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. South & Central America Radiopharmaceutical Theranostics Market, by End User, 2021 & 2028 (%)
Figure 37. Hospitals: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Diagnostic Imaging Centers: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Academic & Research Institutes: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Others: South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. South & Central America: Radiopharmaceutical Theranostics Market, by Key Country – Revenue (2021) (US$ Million)
Figure 42. South & Central America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 43. Brazil Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. Argentina Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. Rest of South & Central America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 46. Growth Strategies in the Radiopharmaceutical Theranostics Market

The List of Companies – South & Central America Radiopharmaceutical Theranostics Market

– Bayer AG
– Curium
– Telix Pharmaceuticals Ltd.
– Siemens Healthineers

Reviews

There are no reviews yet.

Be the first to review “South & Central America Radiopharmaceutical Theranostics Market Forecast to 2028”